Holen Sie sich die Stockscreener-App
59.21
0.13%
-0.12
Schlusskurs vom Vortag:
$59.33
Offen:
$57.99
24-Stunden-Volumen:
1.09M
Relative Volume:
0.52
Marktkapitalisierung:
$11.08B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-16.18
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
+1.86%
1M Leistung:
+26.85%
6M Leistung:
+45.51%
1J Leistung:
+6.05%
1-Tages-Spanne:
$57.74
$59.68
1-Wochen-Bereich:
$56.66
$60.08
52-Wochen-Spanne:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Vergleichen Sie RVMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
59.26 | 11.09B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.60 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.82 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.92 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.38 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines (NASDAQ:RVMD) Now Covered by Analysts at Royal Bank Of Canada - MarketBeat
Revolution Medicines Inc (RVMD) Q3 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Should I hold or sell Revolution Medicines Inc. Equity Warrant stock in 2025Market Trend Review & Daily Stock Momentum Reports - newser.com
What high frequency data says about Revolution Medicines Inc.Trade Risk Assessment & Accurate Technical Buy Alerts - newser.com
How Revolution Medicines Inc. Equity Warrant stock performs in rising dollar environmentJuly 2025 Levels & Real-Time Stock Entry Alerts - newser.com
Real time scanner hits for Revolution Medicines Inc. explainedMarket Risk Analysis & Consistent Return Strategy Ideas - newser.com
Technical signs of recovery in Revolution Medicines Inc.July 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
Order flow analysis tools used on Revolution Medicines Inc.Portfolio Risk Report & AI Driven Price Predictions - newser.com
Will Revolution Medicines Inc. Equity Warrant stock remain a Wall Street favorite2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - newser.com
Revolution Medicines (RVMD) Receives Outperform Rating from RBC Capital - GuruFocus
Revolution Medicines a new outperform at RBC on RAS(ON) inhibitors for cancers - MSN
Revolution Medicines is Best-Positioned to Execute Targeting RAS-Mutated Cancers, RBC Says - MarketScreener
RBC Capital Initiates Coverage on RVMD with an 'Outperform' Rati - GuruFocus
Why Revolution Medicines Inc. (42Z) stock is a strong analyst pickJuly 2025 Setups & Low Risk Profit Maximizing Plans - newser.com
What MACD and RSI say about Revolution Medicines Inc. Equity Warrant2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com
Detecting price anomalies in Revolution Medicines Inc. with AITrade Analysis Summary & Target Return Focused Picks - newser.com
What institutional flow reveals about Revolution Medicines Inc. Equity WarrantMarket Growth Summary & Verified Entry Point Signals - newser.com
Why Revolution Medicines Inc. Equity Warrant stock remains a top recommendation2025 Support & Resistance & Consistent Profit Alerts - newser.com
Applying sector rotation models to Revolution Medicines Inc. Equity WarrantJuly 2025 Review & Daily Chart Pattern Signals - newser.com
Is Revolution Medicines Inc. Equity Warrant showing signs of accumulationMarket Trend Review & Free Reliable Trade Execution Plans - newser.com
RBC Initiates Revolution Medicines at Outperform, Speculative Risk With $77 Price Target - MarketScreener
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
How analysts rate Revolution Medicines Inc. stock today2025 Top Decliners & Reliable Entry Point Alerts - newser.com
Is Revolution Medicines Inc. a candidate for recovery playPortfolio Performance Report & Entry Point Confirmation Signals - newser.com
Revolution Medicines Inc. stock trend outlook and recovery pathJuly 2025 Volume & Real-Time Stock Price Movement Reports - newser.com
Technical signs of recovery in Revolution Medicines Inc. Equity WarrantTrade Analysis Report & Low Drawdown Investment Strategies - newser.com
Visual analytics tools that track Revolution Medicines Inc. Equity Warrant performancePortfolio Update Report & Stepwise Entry/Exit Trade Alerts - newser.com
Is Revolution Medicines Inc. stock a bargain at current levels2025 Key Lessons & High Accuracy Investment Signals - newser.com
How Revolution Medicines Inc. stock performs in rising dollar environmentTrade Ideas & Verified Stock Trade Ideas - newser.com
How Revolution Medicines Inc. (42Z) stock reacts to weak economyMarket Risk Analysis & Reliable Price Action Trade Plans - newser.com
Published on: 2025-11-02 21:21:19 - newser.com
Using Bollinger Bands to evaluate Revolution Medicines Inc. Equity WarrantJuly 2025 Momentum & Risk Managed Investment Entry Signals - newser.com
What makes Revolution Medicines Inc. (42Z) stock appealing to growth investors2025 Market Outlook & Daily Stock Trend Watchlist - newser.com
What to expect from Revolution Medicines Inc. Equity Warrant in the next 30 days2025 Year in Review & Low Drawdown Momentum Ideas - newser.com
Is Revolution Medicines Inc. Equity Warrant stock a buy on dipsEarnings Growth Summary & Low Drawdown Investment Ideas - newser.com
Revolution Medicines shares climb after FDA grants Orphan Drug Designation for pancreatic cancer treatment - MSN
Revolution Medicines Inc. Equity Warrant stock retracement – recovery analysisJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
Published on: 2025-11-02 01:57:56 - newser.com
Revolution Medicines, Inc. (RVMD) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):